Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma, Inc. (INZY)
:INZY
INZY Stock Chart & Stats
$4.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Inozyme Pharma News
INZY FAQ
What was Inozyme Pharma, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Inozyme Pharma, Inc.’s market cap?
Currently, no data Available
When is Inozyme Pharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inozyme Pharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Inozyme Pharma, Inc. overvalued?
According to Wall Street analysts Inozyme Pharma, Inc.’s price is currently Undervalued.
Does Inozyme Pharma, Inc. pay dividends?
Inozyme Pharma, Inc. does not currently pay dividends.
What is Inozyme Pharma, Inc.’s EPS estimate?
Inozyme Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inozyme Pharma, Inc. have?
Currently, no data Available
What happened to Inozyme Pharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inozyme Pharma, Inc.?
Currently, no hedge funds are holding shares in INZY
Company Description
Inozyme Pharma, Inc.
Inozyme Pharma (INZY) is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases characterized by abnormal mineralization. The company aims to address conditions that lead to significant morbidities and mortality due to a lack of effective treatments. Inozyme Pharma's core product candidates target enzyme deficiencies that cause abnormal mineralization in the body, impacting bones, blood vessels, and soft tissues.
Ownership Overview
―
Insiders
0.25%
Mutual Funds
― Other Institutional Investors
99.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---